藍海華騰(300484.SZ):特定股東南橋投資股份減持計劃實施完畢
格隆匯 8 月 4日丨藍海華騰(300484.SZ)公佈,公司於2020年5月26日在巨潮資訊網披露了《關於特定股東股份減持計劃的預披露公告》,特定股東深圳市南橋股權投資基金合夥企業(有限合夥)(以下簡稱"南橋投資")因經營投資資金安排,計劃通過證券交易所集中競價交易、大宗交易方式減持公司股份不超過43萬股(佔公司總股本的比例為0.21%),減持期間為2020年6月16日至2020年12月15日。
2020年8月3日,公司收到南橋投資《關於減持深圳市藍海華騰技術股份有限公司股份的完成情況告知函》,截至2020年8月3日,上述股份減持計劃已實施完畢。於減持期間,南橋投資累計減持43萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.